71 related articles for article (PubMed ID: 15305186)
1. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Ngan SY; Michael M; Mackay J; McKendrick J; Leong T; Lim Joon D; Zalcberg JR
Br J Cancer; 2004 Sep; 91(6):1019-24. PubMed ID: 15305186
[TBL] [Abstract][Full Text] [Related]
2. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C;
Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148
[TBL] [Abstract][Full Text] [Related]
3. A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.
Citrin D; Camphausen K; Wood BJ; Quezado M; Denobile J; Pingpank JF; Royal RE; Alexander HR; Seidel G; Steinberg SM; Shuttack Y; Libutti SK
Oncology; 2010; 79(5-6):382-8. PubMed ID: 21447969
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Lee SU; Kim DY; Kim SY; Baek JY; Chang HJ; Kim MJ; Kim TH; Park JW; Oh JH
Radiat Oncol; 2013 Nov; 8():258. PubMed ID: 24188746
[TBL] [Abstract][Full Text] [Related]
5. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study.
Lupattelli M; Matrone F; Gambacorta MA; Osti M; Macchia G; Palazzari E; Nicosia L; Navarria F; Chiloiro G; Valentini V; Aristei C; De Paoli A
Radiat Oncol; 2017 Aug; 12(1):139. PubMed ID: 28830475
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).
Avallone A; Piccirillo MC; Delrio P; Pecori B; Di Gennaro E; Aloj L; Tatangelo F; D'Angelo V; Granata C; Cavalcanti E; Maurea N; Maiolino P; Bianco F; Montano M; Silvestro L; Terranova Barberio M; Roca MS; Di Maio M; Marone P; Botti G; Petrillo A; Daniele G; Lastoria S; Iaffaioli VR; Romano G; Caracò C; Muto P; Gallo C; Perrone F; Budillon A
BMC Cancer; 2014 Nov; 14():875. PubMed ID: 25421252
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.
Romesser PB; Capdevila J; Garcia-Carbonero R; Philip T; Fernandez Martos C; Tuli R; Rodriguez-Gutierrez A; Kuipers M; Becker A; Coenen-Stass A; Sarholz B; You X; Miller ED
Clin Cancer Res; 2024 Feb; 30(4):695-702. PubMed ID: 38051750
[TBL] [Abstract][Full Text] [Related]
8. An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype.
Guan Y; Shen Y; Xu Y; Li C; Wang J; Gu W; Lian P; Huang D; Cai S; Zhang Z; Zhu J
Therap Adv Gastroenterol; 2019; 12():1756284819852293. PubMed ID: 31217818
[TBL] [Abstract][Full Text] [Related]
9. Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.
Grunda JM; Fiveash J; Palmer CA; Cantor A; Fathallah-Shaykh HM; Nabors LB; Johnson MR
Clin Cancer Res; 2010 May; 16(10):2890-8. PubMed ID: 20460474
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer.
Huang CW; Hu HM; Hsu WH; Chen CY; Huang MY; Chen CP; Wei PL; Shen BN; Wang JY
Nanomedicine (Lond); 2023 Mar; 18(6):511-524. PubMed ID: 37166053
[TBL] [Abstract][Full Text] [Related]
11. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
[TBL] [Abstract][Full Text] [Related]
12. THeragnostic utilities for neoplastic DisEases of the rectum by MRI guided radiotherapy (THUNDER 2) phase II trial: interim safety analysis.
Chiloiro G; Romano A; Cusumano D; Boldrini L; Panza G; Placidi L; Meldolesi E; Nardini M; Meffe G; Nicolini G; Votta C; Indovina L; Gambacorta MA
Radiat Oncol; 2023 Oct; 18(1):163. PubMed ID: 37803322
[TBL] [Abstract][Full Text] [Related]
13. Preoperative short course radiotherapy with concurrent and consolidation chemotherapies followed by delayed surgery in locally advanced rectal cancer: preliminary results.
Aghili M; Sotoudeh S; Ghalehtaki R; Babaei M; Farazmand B; Fazeli MS; Keshvari A; Haddad P; Farhan F
Radiat Oncol J; 2018 Mar; 36(1):17-24. PubMed ID: 29621870
[TBL] [Abstract][Full Text] [Related]
14. Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment.
François E; Magné N; Boulahssass R; Ronchin P; Huguenet V; De Lavigerie B; Nouhaud E; Cattenoz C; Martel-Lafay I; Terret C; Artru P; Clavere P; Tchalla A; Vendrely V; Duc S; Boige V; De Sousa Carvalho N; Gal J; De Bari B
Radiother Oncol; 2024 Apr; 193():110144. PubMed ID: 38341097
[TBL] [Abstract][Full Text] [Related]
15. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Ma WW; Herman JM; Jimeno A; Laheru D; Messersmith WA; Wolfgang CL; Cameron JL; Pawlik TM; Donehower RC; Rudek MA; Hidalgo M
Transl Oncol; 2010 Dec; 3(6):373-9. PubMed ID: 21151476
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.
Bedi M; Das P; Skibber JM; Rodriguez-Bigas MA; Chang GJ; Eng C; Wolff RA; Janjan NA; Krishnan S; Crane CH
Gastrointest Cancer Res; 2007 Mar; 1(2):44-8. PubMed ID: 19262718
[TBL] [Abstract][Full Text] [Related]
17. Degree of tumor regression after preoperative chemo-radiotherapy in locally advanced rectal cancer-Preliminary results.
Mihaylova I; Parvanova V; Velikova C; Kurteva G; Ivanova D
Rep Pract Oncol Radiother; 2011; 16(6):237-42. PubMed ID: 24376987
[TBL] [Abstract][Full Text] [Related]
18. Retracted: Hyperfractionation versus Conventional Fractionation of Preoperative Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer: A Propensity Score Matching Study.
Oncology JO
J Oncol; 2023; 2023():9892163. PubMed ID: 37476561
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind.
Matte P; Ducreux M
Case Rep Oncol; 2023; 16(1):474-477. PubMed ID: 37497421
[TBL] [Abstract][Full Text] [Related]
20. One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials.
Sung SY; Kim DY; Jang HS; Kim TH; Park HC; Chie EK; Nam TK; Kim SH; Lee JH
Cancer Res Treat; 2023 Jul; 55(3):918-926. PubMed ID: 36915252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
